Physician profile
David C Ross
NPI 1922044601
$7,399.74
in general payments reported to CMS, 2019-2025
42 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $1,744 · 2021: $1,707 · 2022: $1,015 · 2023: $595 · 2024: $422 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120 · Education: $45.00 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.44 |
| Education | $45.00 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,995.75 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,044.77 | 2019-2025 | Mounjaro, Taltz, Jardiance |
| Abbott Laboratories | $633.48 | 2020-2025 | Freestyle Libre 3, Merlin@Home, Freestyle Insulinx |
| Sanofi-Aventis U.S. LLC | $518.65 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $480.80 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $312.53 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $272.60 | 2019-2023 | Breztri |
| Becton, Dickinson and Company | $183.39 | 2019-2021 | |
| Amgen INC. | $171.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.15 | 2021-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $146.37 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $127.97 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $110.73 | 2019-2023 | Omnipod |
| Amarin Pharma, INC. | $107.90 | 2019-2021 | |
| Glaxosmithkline, LLC. | $99.19 | 2022-2023 | Trelegy Ellipta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.